Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to enhance neurological symptoms of Ataxia-Telangiectasia (A-T); and GTX-101, a topical bio adhesive film-forming bupivacaine spray for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.…
Grace Therapeutics Announces Second Quarter 2027 Financial Results, Provides Business Update
Grace Therapeutics (NASDAQ: GRCE) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 5 employees.
The shares were at 1.710 USD on 20 November 2026, down 43.6% over 52 weeks. Its 52-week range is 1.640 USD to 5.180 USD: the price is 67.0% below the high and 4.3% above the low.
Its market capitalisation is 35.97M USD.
Grace Therapeutics reports return on equity of -12.2% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 13.76M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. 2 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 5.817 USD is 240.2% above the current price.